NO320884B1 - Anvendelse av lysostafin eller variant derav til fremstilling av et medikament til behandling av infeksjoner. - Google Patents
Anvendelse av lysostafin eller variant derav til fremstilling av et medikament til behandling av infeksjoner. Download PDFInfo
- Publication number
- NO320884B1 NO320884B1 NO20000314A NO20000314A NO320884B1 NO 320884 B1 NO320884 B1 NO 320884B1 NO 20000314 A NO20000314 A NO 20000314A NO 20000314 A NO20000314 A NO 20000314A NO 320884 B1 NO320884 B1 NO 320884B1
- Authority
- NO
- Norway
- Prior art keywords
- lysostaphin
- use according
- infection
- vancomycin
- doses
- Prior art date
Links
- 108090000988 Lysostaphin Proteins 0.000 title claims abstract description 135
- 208000015181 infectious disease Diseases 0.000 title claims description 51
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 238000011282 treatment Methods 0.000 title description 32
- 239000003814 drug Substances 0.000 title description 8
- 206010041925 Staphylococcal infections Diseases 0.000 claims abstract description 13
- 238000007911 parenteral administration Methods 0.000 claims abstract description 8
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims abstract description 7
- 108010059993 Vancomycin Proteins 0.000 claims description 30
- 229960003165 vancomycin Drugs 0.000 claims description 30
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 30
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 30
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 16
- 241000295644 Staphylococcaceae Species 0.000 claims description 16
- 229960003085 meticillin Drugs 0.000 claims description 16
- 239000004599 antimicrobial Substances 0.000 claims description 14
- 206010014665 endocarditis Diseases 0.000 claims description 13
- 239000004471 Glycine Substances 0.000 claims description 8
- 210000003709 heart valve Anatomy 0.000 claims description 8
- 210000003734 kidney Anatomy 0.000 claims description 8
- 210000002421 cell wall Anatomy 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 230000002797 proteolythic effect Effects 0.000 claims description 6
- 208000031729 Bacteremia Diseases 0.000 claims description 5
- 241000191967 Staphylococcus aureus Species 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 5
- 108010015899 Glycopeptides Proteins 0.000 claims description 4
- 102000002068 Glycopeptides Human genes 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 206010031252 Osteomyelitis Diseases 0.000 claims description 3
- 229930189077 Rifamycin Natural products 0.000 claims description 3
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims 1
- 210000002418 meninge Anatomy 0.000 claims 1
- 229960003292 rifamycin Drugs 0.000 claims 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical group OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 abstract description 24
- 102000004190 Enzymes Human genes 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 24
- 241000894006 Bacteria Species 0.000 abstract description 16
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 239000003242 anti bacterial agent Substances 0.000 abstract description 6
- 229930182555 Penicillin Natural products 0.000 abstract description 5
- 229940088710 antibiotic agent Drugs 0.000 abstract description 4
- 150000002960 penicillins Chemical class 0.000 abstract description 4
- 230000000941 anti-staphylcoccal effect Effects 0.000 abstract description 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- 230000000844 anti-bacterial effect Effects 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 235000015097 nutrients Nutrition 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000000845 anti-microbial effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 241000193386 Lysinibacillus sphaericus Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 108010059378 Endopeptidases Proteins 0.000 description 3
- 102000005593 Endopeptidases Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 206010014684 Endocarditis staphylococcal Diseases 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 2
- 229940081192 rifamycins Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000006150 trypticase soy agar Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000031462 Bovine Mastitis Diseases 0.000 description 1
- 206010057651 Cardiac valve vegetation Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 102000009338 Gastric Mucins Human genes 0.000 description 1
- 108010009066 Gastric Mucins Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000023146 Pre-existing disease Diseases 0.000 description 1
- 206010051017 Staphylococcal bacteraemia Diseases 0.000 description 1
- 241001147736 Staphylococcus capitis Species 0.000 description 1
- 241000191978 Staphylococcus simulans Species 0.000 description 1
- 241000191976 Staphylococcus simulans bv. staphylolyticus Species 0.000 description 1
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 1
- 238000010161 Student-Newman-Keuls test Methods 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- 241000748245 Villanova Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 206010038351 renal abscess Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 229940037648 staphylococcus simulans Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24075—Lysostaphin (3.4.24.75)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5347097P | 1997-07-23 | 1997-07-23 | |
| PCT/US1998/015257 WO1999004809A1 (fr) | 1997-07-23 | 1998-07-21 | Compositions pharmaceutiques renfermant de la lysostaphine seule ou en combinaison avec un antibiotique pour le traitement des infections staphylococciques |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20000314D0 NO20000314D0 (no) | 2000-01-21 |
| NO20000314L NO20000314L (no) | 2000-03-16 |
| NO320884B1 true NO320884B1 (no) | 2006-02-06 |
Family
ID=21984478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20000314A NO320884B1 (no) | 1997-07-23 | 2000-01-21 | Anvendelse av lysostafin eller variant derav til fremstilling av et medikament til behandling av infeksjoner. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20020006406A1 (fr) |
| EP (1) | EP1001804B1 (fr) |
| JP (1) | JP2001510805A (fr) |
| KR (1) | KR20010022237A (fr) |
| CN (1) | CN1269727A (fr) |
| AT (1) | ATE316794T1 (fr) |
| AU (1) | AU754806B2 (fr) |
| BR (1) | BR9811535A (fr) |
| CA (1) | CA2297083C (fr) |
| DE (1) | DE69833377T2 (fr) |
| HU (1) | HUP0002662A3 (fr) |
| IL (1) | IL134056A0 (fr) |
| NO (1) | NO320884B1 (fr) |
| NZ (1) | NZ502359A (fr) |
| PL (1) | PL338178A1 (fr) |
| RU (1) | RU2234940C2 (fr) |
| SK (1) | SK732000A3 (fr) |
| TW (1) | TWI235656B (fr) |
| WO (1) | WO1999004809A1 (fr) |
| ZA (1) | ZA986593B (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6423299B1 (en) | 1997-10-31 | 2002-07-23 | Vincent Fischetti | Composition for treatment of a bacterial infection of an upper respiratory tract |
| US6428784B1 (en) | 1997-10-31 | 2002-08-06 | New Horizons Diagnostics Corp | Vaginal suppository for treating group B Streptococcus infection |
| US7232576B2 (en) | 1997-10-31 | 2007-06-19 | New Horizons Diagnostics Corp | Throat lozenge for the treatment of Streptococcus Group A |
| US6277399B1 (en) | 1997-10-31 | 2001-08-21 | New Horizon Diagnostics Corporation | Composition incorporating bacterial phage associated lysing enzymes for treating dermatological infections |
| US6056954A (en) * | 1997-10-31 | 2000-05-02 | New Horizons Diagnostics Corp | Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses |
| US6399097B1 (en) | 1997-10-31 | 2002-06-04 | New Horizons Diagnostics Corporation | Composition for treatment of a bacterial infection of the digestive tract |
| US6432444B1 (en) | 1997-10-31 | 2002-08-13 | New Horizons Diagnostics Corp | Use of bacterial phage associated lysing enzymes for treating dermatological infections |
| US6399098B1 (en) | 1997-10-31 | 2002-06-04 | New Horizons Diagnostics Corp | Composition for treating dental caries caused by streptococcus mutans |
| US6406692B1 (en) | 1997-10-31 | 2002-06-18 | New Horizons Diagnostics Corp | Composition for treatment of an ocular bacterial infection |
| US6569830B1 (en) | 1999-03-05 | 2003-05-27 | Ambi, Inc. | Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains |
| US20020127215A1 (en) * | 1999-09-14 | 2002-09-12 | Lawrence Loomis | Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| AU2001259205A1 (en) * | 2000-04-28 | 2001-11-12 | New Horizons Diagnostic Corporation | The use of bacterial phage associated lysing enzymes for treating various illnesses |
| US6395504B1 (en) | 2000-09-01 | 2002-05-28 | New Horizons Diagnostics Corp. | Use of phage associated lytic enzymes for the rapid detection of bacterial contaminants |
| US7572439B2 (en) * | 2002-03-26 | 2009-08-11 | Biosynexus Incorporated | Enzyme disruption of bacterial biofilms |
| EP1567868A4 (fr) * | 2002-12-02 | 2008-02-06 | Biosynexus Inc | Acide teichoique a paroi en tant que cible pour therapies et vaccins anti-staphylococciques |
| CN1744905A (zh) * | 2002-12-10 | 2006-03-08 | 百敖新纳斯有限公司 | 局部抗感染制剂 |
| US20100221237A1 (en) * | 2003-03-26 | 2010-09-02 | Biosynexus Incorporated | Enzyme disruption of bacterial biofilms |
| WO2006076058A1 (fr) * | 2005-01-10 | 2006-07-20 | Nabi Biopharmaceuticals | Methode de traitement d'une infection par staphylocoque dore |
| EP1885403B1 (fr) | 2005-04-12 | 2013-05-08 | Nektar Therapeutics | Conjugués de la lysostaphine et du poly(éthylène glycol) |
| US7943128B2 (en) | 2006-03-31 | 2011-05-17 | The University Court Of The University Of St Andrews | Anti-microbial compositions comprising a cationic peptide and a glycylglycine endopeptidase |
| CN101437532B (zh) | 2006-05-05 | 2013-08-21 | 冈戈根股份有限公司 | 噬菌体衍生的抗微生物活性剂 |
| WO2009114520A2 (fr) * | 2008-03-10 | 2009-09-17 | Pharmain Corporation | Compositions de traitement ayant des métallopeptidases, procédés de fabrication et utilisation de celles-ci |
| WO2009150171A1 (fr) * | 2008-06-10 | 2009-12-17 | Profos Ag | Procédé de traitement de maladies inflammatoires |
| US11155801B2 (en) | 2013-08-06 | 2021-10-26 | Trustees Of Dartmouth College | Unglycosylated lysostaphin variant protein |
| RU2572341C2 (ru) * | 2013-09-20 | 2016-01-10 | Федеральное государственное бюджетное учреждение Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе Российской академии медицинских наук (ФГБУ "НИИНА" РАМН) | АНТИБИОТИК ИНА 5812, ШТАММ-ПРОДУЦЕНТ Streptomyces roseoflavus ИНА-Ас-5812 И СПОСОБ ПОЛУЧЕНИЯ АНТИБИОТИКА |
| EP3485899A4 (fr) * | 2017-09-25 | 2020-05-20 | Georgy Georgievich Chumburidze | Composition thermostable possédant une action antivirale et antibactérienne, et utilisation de celle-ci |
| US11565024B2 (en) | 2017-11-16 | 2023-01-31 | Georgia Tech Research Corporation | Lysostaphin containing synthetic hydrogel carriers for bone repair |
| CN110917339B (zh) * | 2019-12-27 | 2023-07-07 | 遵义医学院附属医院 | 一种溶葡萄球菌酶凝胶剂及其在mrsa感染创面中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5858962A (en) * | 1987-05-11 | 1999-01-12 | Ambi Inc. | Composition for treating mastitis and other staphylococcal infections |
| AU623864B2 (en) * | 1988-08-29 | 1992-05-28 | Applied Microbiology, Inc | Method of treating mastitis and other staphylococcal infections |
-
1998
- 1998-07-21 JP JP2000503861A patent/JP2001510805A/ja active Pending
- 1998-07-21 CA CA002297083A patent/CA2297083C/fr not_active Expired - Fee Related
- 1998-07-21 EP EP98935954A patent/EP1001804B1/fr not_active Expired - Lifetime
- 1998-07-21 US US09/120,030 patent/US20020006406A1/en not_active Abandoned
- 1998-07-21 CN CN98808669A patent/CN1269727A/zh active Pending
- 1998-07-21 DE DE69833377T patent/DE69833377T2/de not_active Expired - Lifetime
- 1998-07-21 AT AT98935954T patent/ATE316794T1/de not_active IP Right Cessation
- 1998-07-21 NZ NZ502359A patent/NZ502359A/en unknown
- 1998-07-21 PL PL98338178A patent/PL338178A1/xx not_active Application Discontinuation
- 1998-07-21 BR BR9811535-9A patent/BR9811535A/pt not_active IP Right Cessation
- 1998-07-21 AU AU85095/98A patent/AU754806B2/en not_active Ceased
- 1998-07-21 HU HU0002662A patent/HUP0002662A3/hu unknown
- 1998-07-21 SK SK73-2000A patent/SK732000A3/sk unknown
- 1998-07-21 WO PCT/US1998/015257 patent/WO1999004809A1/fr not_active Application Discontinuation
- 1998-07-21 IL IL13405698A patent/IL134056A0/xx unknown
- 1998-07-21 KR KR1020007000810A patent/KR20010022237A/ko not_active Application Discontinuation
- 1998-07-21 RU RU2000104516/15A patent/RU2234940C2/ru not_active IP Right Cessation
- 1998-07-23 ZA ZA986593A patent/ZA986593B/xx unknown
- 1998-08-29 TW TW087112047A patent/TWI235656B/zh not_active IP Right Cessation
-
2000
- 2000-01-21 NO NO20000314A patent/NO320884B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI235656B (en) | 2005-07-11 |
| CN1269727A (zh) | 2000-10-11 |
| EP1001804A1 (fr) | 2000-05-24 |
| HUP0002662A2 (hu) | 2000-12-28 |
| DE69833377T2 (de) | 2006-11-16 |
| NO20000314L (no) | 2000-03-16 |
| NZ502359A (en) | 2005-02-25 |
| US20020006406A1 (en) | 2002-01-17 |
| BR9811535A (pt) | 2000-08-29 |
| HUP0002662A3 (en) | 2003-08-28 |
| KR20010022237A (ko) | 2001-03-15 |
| ZA986593B (en) | 1999-02-04 |
| NO20000314D0 (no) | 2000-01-21 |
| WO1999004809A1 (fr) | 1999-02-04 |
| PL338178A1 (en) | 2000-10-09 |
| CA2297083A1 (fr) | 1999-02-04 |
| JP2001510805A (ja) | 2001-08-07 |
| HU0002662D0 (en) | 2000-08-28 |
| AU754806B2 (en) | 2002-11-28 |
| CA2297083C (fr) | 2007-10-30 |
| RU2234940C2 (ru) | 2004-08-27 |
| EP1001804B1 (fr) | 2006-02-01 |
| AU8509598A (en) | 1999-02-16 |
| SK732000A3 (en) | 2001-03-12 |
| IL134056A0 (en) | 2001-04-30 |
| ATE316794T1 (de) | 2006-02-15 |
| DE69833377D1 (de) | 2006-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU754806B2 (en) | Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections | |
| US7572439B2 (en) | Enzyme disruption of bacterial biofilms | |
| US6028051A (en) | Method for the treatment of staphylococcal disease | |
| EP2822582B1 (fr) | Vaccin multivalent protégeant de l'infection à staphylococcus aureus | |
| US20100221237A1 (en) | Enzyme disruption of bacterial biofilms | |
| US10220112B2 (en) | Cyclic antimicrobial pseudopeptides and uses thereof | |
| EP1671644A2 (fr) | Compositions pharmaceutiques contenant uniquement ou en combinaison avec un antibiotique de la lysostaphin pour le traitement des infections à staphylocoques | |
| US20220160842A1 (en) | Method of treating infective endocarditis | |
| CA3136461A1 (fr) | Methode de traitement et de prevention d'infections osseuses et articulaires | |
| AU2004201269B2 (en) | A method for the treatment of staphylocccal disease | |
| CN111569079B (zh) | 一种抗葡萄球菌感染的抗体抗生素联合制剂 | |
| CZ2000144A3 (cs) | Farmaceutické kompozice obsahující lysostafin, samotné nebo v kombinaci s antibiotikem, pro léčbu stafylokokových infekcí | |
| US20210252083A1 (en) | Bacteriophage compositions for treating staphylococcus infection | |
| WO2023081691A1 (fr) | Procédé de traitement et de prévention d'infections osseuses et articulaires |